- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 231
UL takes a risk on KenSci in $22m round
UL Ventures' parent company will offer assistance in growth and compliance to the healthcare risk assessment platform developer, which has just raised series B funding.
Feb 12, 2019KenSci foretells $22m series B
The UW-founded healthcare forecasting software developer has collected $30.5m in all from backers including OUP and a unit of compliance firm UL.
Feb 12, 2019Cisco hits Gong in $40m series B
Existing investor Cisco chipped in for a series B round that boosted sales data platform Gong.io's overall funding to $68m.
Feb 11, 2019Amazon drives $530m in funding for Aurora
Amazon and Shell have invested in driverless car software and hardware developer Aurora Innovation at a valuation above $2.5bn, in a round led by Sequoia Capital.
Feb 8, 2019Spin Memory banks Abies for series B
NYU and Allied Minds-founded Ram technology developer Spin Memory has unveiled deep tech-focused VC firm Abies Ventures as an investor in a $52m series B first announced late last year.
Feb 8, 2019Calm meditates on $88m series B
The meditation app developer has quadrupled its valuation to $1bn in just eight months, in an $88m series B round featuring CAA.
Feb 7, 2019Aetion advances series B past $63m
Sanofi, UCB, Horizon Health Services and McKesson Ventures added $27m to a series B round for the medical data software provider that already included Amgen Ventures.
Feb 7, 2019Healthy.io takes home $18m
Samsung Next has taken part in a series B round that will fund the roll out of Healthy.io's home urinalysis analyser system in the UK and expansion in the US.
Feb 7, 2019Vinli makes tracks with Eon-backed series B
The automotive data platform developer, which counts Samsung, Cox Enterprises and Continental as shareholders, has secured $13.5m in its series B round.
Feb 7, 2019Bolt hits series B with $54m
Nan Fung Life Sciences and Novo have taken part in a series B round for Stanford's immuno-oncology drug developer Bolt Biotherapeutics.
Feb 6, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


